Table 3: Next Generation Sequencing Profile Characteristics.
Next Generation Sequencing profile, exhibited as the percentage of patients who expressed an individual gene in responders to immunotherapy compared to patients with SD or PDiii.
| Gene | Responders n=27 |
SD or PD n=40 |
p-value |
|---|---|---|---|
| APC | 1 (4.2%) | 2 (6.1%) | 1.000 |
| ATM | 0 (0.0%) | 1 (4.4%) | 1.000 |
| BRAF | 7 (29.2%) | 14 (40.0%) | 0.423 |
| CDKN2A | 1 (4.2%) | 5 (15.6%) | 0.223 |
| CTNNB1 | 0 (0.0%) | 1 (3.1%) | 1.000 |
| EGFR | 2 (8.3%) | 1 (3.1%) | 0.571 |
| FBXW7 | 1 (4.2%) | 1 (3.1%) | 1.000 |
| FGFR2 | 0 (0.0%) | 1 (3.1%) | 1.000 |
| FGFR3 | 0 (0.0%) | 1 (3.1%) | 1.000 |
| FLT3 | 0 (0.0%) | 2 (6.3%) | 0.501 |
| GNAS | 1 (4.2%) | 1 (3.1%) | 1.000 |
| IDH1 | 1 (4.2%) | 1 (3.1%) | 1.000 |
| JAK2 | 0 (0.0%) | 1 (5.3%) | 1.000 |
| KDR | 0 (0.0%) | 1 (3.1%) | 1.000 |
| KIT | 0 (0.0%) | 1 (2.9%) | 1.000 |
| KIT EXON13 | 0 (0.0%) | 1 (3.0%) | 1.000 |
| KRAS | 0 (0.0%) | 1 (3.1%) | 1.000 |
| MET | 0 (0.0%) | 1 (3.1%) | 1.000 |
| NRAS | 13 (54.2%) | 8 (25.0%) | 0.050 |
| PDGFRA | 0 (0.0%) | 1 (3.1%) | 1.000 |
| PTEN | 1 (4.2%) | 2 (6.3%) | 1.000 |
| RB1 | 1 (4.2%) | 1 (3.1%) | 1.000 |
| TP53 | 5 (20.8%) | 7 (21.9%) | 1.000 |
iii
No mutation in this cohort was found in the following genes: ABL1, AKT1, ALK, CDH1, CSF1R, ERBB4, FGFR1, GNA11, GNAQ, HNF1A, HRAS, IDH2, JAK3, MLH1, MPL, NOTCH1, NPM1, PIK3CA, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, VHL. Missing values were excluded for the analysis.